Mechanistic Evaluation of Response in TRD (MERIT)

Summary

To evaluate the relapse prevention of AXS-05 relative to placebo in subjects with treatment resistant depression (TRD). This is a randomized, double-blind, placebo-controlled study to evaluate AXS-05 compared to placebo in delaying relapse of depressive symptoms in patients with TRD who are in stable remission after treatment with AXS-05.

Timeline

Start

2020-08-13

Primary completion

2021-07-30

Completion

2021-07-30

Outcome

Met primary endpoint

release “met the primary and key secondary endpoints in the MERIT (Mechanistic Evaluation of Response in TRD) Phase 2 trial” gcs-web.com ↗

Drugs

Indications